INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
03 · Corporate insiders

Form 4 filings

Officers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.

Form 4 transactions

Cluster activity · 60d

Most active filers

Companies with the most Form 4 filings
Data sources
SEC Form 42h ago
House PTR2h ago
SEC 13F2h ago
Robinhood Chain2h ago

Most active filers · 30d

  1. 01Kurtz George0B / 217S · 10 late217 trades$54.77M
  2. 02SPSaba Capital Management, L.P.55B / 19S · 3 late74 trades$23.87M
  3. 03ATAdair Kathleen Theresa52B / 0S · 52 late52 trades$18K
  4. 04CFCheng Chi Fung0B / 42S42 trades$15.33M
  5. 05RARothblatt Martine A0B / 33S33 trades$5.50M
  6. 06RJRubinstein Julie0B / 32S32 trades$5.55M
  7. 07LBLeach Bryan0B / 30S30 trades$7.97M
  8. 08AOAtay Oguzhan0B / 30S30 trades$7.55M
  9. 09JDJenkins William D Jr0B / 30S30 trades$13.38M
  10. 10BSBiswas Sanjit0B / 28S28 trades$22.33M

Cluster activity · 60d

  1. SELLDRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
  2. SELLFERGFerguson Enterprises Inc. /DE/Oct 12 – Oct 167 insiders$7.38M
  3. SELLSYMSymbotic Inc.Oct 26 – Nov 27 insiders$1.98M
  4. BUYUPBDUPBOUND GROUP, INC.Nov 2 – Nov 37 insiders$1.34M
  5. SELLIBEXIBEX LtdSep 14 – Sep 166 insiders$2.01M
  6. SELLARQQArqit Quantum Inc.Oct 2 – Oct 136 insiders$369K
  7. BUYBBTBeacon Financial CorpOct 26 – Oct 306 insiders$274K
  8. SELLBCYCBICYCLE THERAPEUTICS PLCOct 2 – Oct 56 insiders$63K

Form 4 transactions

21,251 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
Include
grants & admin
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
15
MS
Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
NTRANatera, Inc.
Open-market sale · 10b5-1 plan
SELL$710K
2,600 sh
Jul 1, 2026Jul 6, 2026
traded Jul 1, 2026
+5dSEC Form 4

Evidence

15
HM
Hancock MarkDirector, 10% Owner
PACSPACS Group, Inc.
Open-market sale · 10b5-1 plan
SELL$274K
6,080 sh
Jul 1, 2026Jul 6, 2026
traded Jul 1, 2026
+5dSEC Form 4

Evidence

15
LR
Lewis Michelle ReneeChief Accounting Officer
PACSPACS Group, Inc.
Open-market sale · 10b5-1 plan
SELL$189K
4,200 sh
Jul 1, 2026Jul 6, 2026
traded Jul 1, 2026
+5dSEC Form 4

Evidence

14
FW
Ford Russell WayneDirector, Chief Executive Officer
SAROStandardAero, Inc.
Open-market sale · 10b5-1 plan
SELL$1.21M
40.0K sh
Jul 2, 2026Jul 6, 2026
traded Jul 2, 2026
+4dSEC Form 4

Evidence

14
SH
Sehmi HarminderChief Financial Officer
BZAIBlaize Holdings, Inc.
Open-market sale · 10b5-1 plan
SELL$56K
40.6K sh
Jul 1, 2026Jul 6, 2026
traded Jul 1, 2026
+5dSEC Form 4

Evidence

13
RM
Roth James MChief Revenue Officer
GTMZoomInfo Technologies Inc.
Open-market sale · 10b5-1 plan
SELL$62K
20.8K sh
Jul 2, 2026Jul 6, 2026
traded Jul 2, 2026
+4dSEC Form 4

Evidence

12
LM
Lin MarkEVP and CFO
SMTCSEMTECH CORP
Open-market sale · 10b5-1 plan
SELL$146K
970 sh
Jul 1, 2026Jul 6, 2026
traded Jul 1, 2026
+5dSEC Form 4

Evidence

12
HM
Hancock MarkDirector, 10% Owner
PACSPACS Group, Inc.
Open-market sale · 10b5-1 plan
SELL$6.44M
142.2K sh
Jul 6, 2026Jul 6, 2026
traded Jul 6, 2026
+0dSEC Form 4

Evidence

12
LR
Lewis Michelle ReneeChief Accounting Officer
PACSPACS Group, Inc.
Open-market sale · 10b5-1 plan
SELL$300K
6,663 sh
Jul 2, 2026Jul 6, 2026
traded Jul 2, 2026
+4dSEC Form 4

Evidence

12
MS
Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
NTRANatera, Inc.
Open-market sale · 10b5-1 plan
SELL$82K
300 sh
Jul 1, 2026Jul 6, 2026
traded Jul 1, 2026
+5dSEC Form 4

Evidence

10
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$338K
1,081 sh
Jul 1, 2026Jul 6, 2026
traded Jul 1, 2026
+5dSEC Form 4

Evidence

10
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$349K
1,119 sh
Jul 1, 2026Jul 6, 2026
traded Jul 1, 2026
+5dSEC Form 4

Evidence

10
CK
Clark KyleDirector, SEE REMARKS
BETABETA Technologies, Inc.
Open-market sale · 10b5-1 plan
SELL$261K
15.0K sh
Jul 1, 2026Jul 6, 2026
traded Jul 1, 2026
+5dSEC Form 4

Evidence

10
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$284K
900 sh
Jul 1, 2026Jul 6, 2026
traded Jul 1, 2026
+5dSEC Form 4

Evidence

9
HM
Hancock MarkDirector, 10% Owner
PACSPACS Group, Inc.
Open-market sale · 10b5-1 plan
SELL$577K
12.8K sh
Jul 2, 2026Jul 6, 2026
traded Jul 2, 2026
+4dSEC Form 4

Evidence

9
LR
Lewis Michelle ReneeChief Accounting Officer
PACSPACS Group, Inc.
Open-market sale · 10b5-1 plan
SELL$186K
4,137 sh
Jul 6, 2026Jul 6, 2026
traded Jul 6, 2026
+0dSEC Form 4

Evidence

9
RH
Robinson Mark HaymondGeneral Counsel and Secretary
GMEGameStop Corp.
Open-market sale · 10b5-1 plan
SELL$90K
3,957 sh
Jul 6, 2026Jul 6, 2026
traded Jul 6, 2026
+0dSEC Form 4

Evidence

9
MS
Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
NTRANatera, Inc.
Open-market sale · 10b5-1 plan
SELL$27K
100 sh
Jul 1, 2026Jul 6, 2026
traded Jul 1, 2026
+5dSEC Form 4

Evidence

8
JD
Johnston James DavidExecutive VP, GC, CCO and Secy
SMCSummit Midstream Corp
Open-market sale · 10b5-1 plan
SELL$77K
2,600 sh
Jul 2, 2026Jul 6, 2026
traded Jul 2, 2026
+4dSEC Form 4

Evidence

8
BS
Beatty Jonathan SMD, Head of Advisor Services
SCHWSCHWAB CHARLES CORP
Open-market sale · 10b5-1 plan
SELL$200K
2,000 sh
Jul 6, 2026Jul 6, 2026
traded Jul 6, 2026
+0dSEC Form 4

Evidence

8
MR
Marion Josh R.SVP and General Counsel
KOSKosmos Energy Ltd.
Open-market sale · 10b5-1 plan
SELL$51K
25.0K sh
Jul 2, 2026Jul 6, 2026
traded Jul 2, 2026
+4dSEC Form 4

Evidence

8
BS
Beatty Jonathan SMD, Head of Advisor Services
SCHWSCHWAB CHARLES CORP
Open-market sale · 10b5-1 plan
SELL$194K
2,000 sh
Jul 2, 2026Jul 6, 2026
traded Jul 2, 2026
+4dSEC Form 4

Evidence

8
KA
Kerdman AlinaSVP, Controller & CAO
CTSHCOGNIZANT TECHNOLOGY SOLUTIONS CORP
Open-market sale · 10b5-1 plan
SELL$5,455
137 sh
Jul 1, 2026Jul 6, 2026
traded Jul 1, 2026
+5dSEC Form 4

Evidence

7
LD
Lentz DanielCFO & COO
CMRCCommerce.com, Inc.
Open-market sale · 10b5-1 plan
SELL$4,570
1,544 sh
Jul 1, 2026Jul 6, 2026
traded Jul 1, 2026
+5dSEC Form 4

Evidence

7
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$190K
600 sh
Jul 1, 2026Jul 6, 2026
traded Jul 1, 2026
+5dSEC Form 4

Evidence

7
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$122K
396 sh
Jul 1, 2026Jul 6, 2026
traded Jul 1, 2026
+5dSEC Form 4

Evidence

7
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$219K
700 sh
Jul 1, 2026Jul 6, 2026
traded Jul 1, 2026
+5dSEC Form 4

Evidence

4
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$32K
104 sh
Jul 1, 2026Jul 6, 2026
traded Jul 1, 2026
+5dSEC Form 4

Evidence

4
CK
Clark KyleDirector, SEE REMARKS
BETABETA Technologies, Inc.
Open-market sale · 10b5-1 plan
SELL$269K
15.0K sh
Jul 2, 2026Jul 6, 2026
traded Jul 2, 2026
+4dSEC Form 4

Evidence

4
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$31K
100 sh
Jul 1, 2026Jul 6, 2026
traded Jul 1, 2026
+5dSEC Form 4

Evidence

3
DS
Dutt SubirChief Sales Officer
XMTRXometry, Inc.
Open-market sale · 10b5-1 plan
SELL$29K
310 sh
Jul 2, 2026Jul 6, 2026
traded Jul 2, 2026
+4dSEC Form 4

Evidence

3
RV
Raghavan VaidyanathanChief Technology Officer
XMTRXometry, Inc.
Open-market sale · 10b5-1 plan
SELL$5,734
59 sh
Jul 2, 2026Jul 6, 2026
traded Jul 2, 2026
+4dSEC Form 4

Evidence

3
RV
Raghavan VaidyanathanChief Technology Officer
XMTRXometry, Inc.
Open-market sale · 10b5-1 plan
SELL$31K
326 sh
Jul 2, 2026Jul 6, 2026
traded Jul 2, 2026
+4dSEC Form 4

Evidence

3
DS
Dutt SubirChief Sales Officer
XMTRXometry, Inc.
Open-market sale · 10b5-1 plan
SELL$5,151
53 sh
Jul 2, 2026Jul 6, 2026
traded Jul 2, 2026
+4dSEC Form 4

Evidence

3
DS
Dutt SubirChief Sales Officer
XMTRXometry, Inc.
Open-market sale · 10b5-1 plan
SELL$19K
199 sh
Jul 2, 2026Jul 6, 2026
traded Jul 2, 2026
+4dSEC Form 4

Evidence

3
RV
Raghavan VaidyanathanChief Technology Officer
XMTRXometry, Inc.
Open-market sale · 10b5-1 plan
SELL$49K
529 sh
Jul 2, 2026Jul 6, 2026
traded Jul 2, 2026
+4dSEC Form 4

Evidence

3
RV
Raghavan VaidyanathanChief Technology Officer
XMTRXometry, Inc.
Open-market sale · 10b5-1 plan
SELL$9,391
99 sh
Jul 2, 2026Jul 6, 2026
traded Jul 2, 2026
+4dSEC Form 4

Evidence

3
RV
Raghavan VaidyanathanChief Technology Officer
XMTRXometry, Inc.
Open-market sale · 10b5-1 plan
SELL$39K
428 sh
Jul 2, 2026Jul 6, 2026
traded Jul 2, 2026
+4dSEC Form 4

Evidence

3
DS
Dutt SubirChief Sales Officer
XMTRXometry, Inc.
Open-market sale · 10b5-1 plan
SELL$25K
274 sh
Jul 2, 2026Jul 6, 2026
traded Jul 2, 2026
+4dSEC Form 4

Evidence

3
DS
Dutt SubirChief Sales Officer
XMTRXometry, Inc.
Open-market sale · 10b5-1 plan
SELL$9,483
100 sh
Jul 2, 2026Jul 6, 2026
traded Jul 2, 2026
+4dSEC Form 4

Evidence

Page 208 of 532
← PrevNext →